EUVIMEDDécouvrir EUVIMED
CrossrefCarte d’information

Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta‐analysis

Noémie Fournier, Panagiotis Antiochos, Baris Gencer, Anna Nowacka, Tamila Abdurashidova, Patrick Yerly, Philippe Meyer, Valentina Rancati, Zied Ltaief, Olivier Muller, Matthias Kirsch, Roger Hullin, Henri Lu

Clinical Transplantation · 2026-11 · 40 (11)

DOI: 10.1111/ctr.70742 ↗
RésuméRéférences bibliographiques

Résumé

Abstract Background Cardiac allograft vasculopathy (CAV) remains a major cause of late graft failure and morbidity among heart transplant (HTx) recipients. Aspirin is currently assigned a Class IIb recommendation for CAV prevention, reflecting the limited evidence supporting its clinical benefit. We conducted a systematic review and meta‐analysis to assess the association between aspirin use and clinical outcomes in HTx recipients (PROSPERO ID: CRD420261399873). Methods: Outcomes of interest included all‐cause mortality and CAV‐related clinical outcomes (graft dysfunction or CAV‐related death). Literature searches were conducted through December 2025 in PubMed and EMBASE. Studies comparing HTx recipients treated with aspirin versus no aspirin were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were meta‐analyzed across studies. Results Five observational studies were included, comprising four adult cohorts and one pediatric cohort. Participants were predominantly male (66.6%), with a mean age of ≈50 years in the four adult studies and 7.4 years in the sole pediatric study. Aspirin use was associated with significantly lower all‐cause mortality (four studies, HR 0.31 [95% CI: 0.15–0.67]). No statistically significant association was observed with CAV‐related clinical outcomes (HR 0.42 [95% CI: 0.10–1.77]). Conclusions In HTx recipients, aspirin use was associated with lower all‐cause mortality, while no significant association was observed in the exploratory analysis of CAV‐related clinical outcomes. These findings should be interpreted cautiously given the observational design, substantial heterogeneity, and potential residual and time‐related biases. Prospective studies are needed to determine the efficacy and safety of aspirin after HTx.

Des connaissances adaptées à votre travail.

D’un démarrage gratuit à la Research Suite complète, en passant par la recherche bibliographique personnelle.

Voir les tarifs →

Tous les textes intégraux sont-ils inclus ?

Non. Notices, résumés et textes intégraux sont des contenus distincts. La disponibilité dépend de la source, de l’accès ouvert et de vos licences. Une offre EUVIMED ne remplace pas des droits supplémentaires auprès des éditeurs.

Voir les tarifs →